Dew, board, Any thoughts on likely bio buyout candidates? Some of the frequently mentioned names I've seen include - Onyx (Bayer) Alexion Watson United Therapeutics Vertex (J+J) Amylin (Lilly) Some others - Pharmasset (Roche) Biomarin (Genzyme) Abraxis Momenta (Novartis) GTCB Medarex Amag Middlebrook OSI Pharma Xenoport Invitrogen Sequenom Any thoughts on these, or other ideas? Thanks. <!--Beg_Sig-->